CLRB
Closed
Cellectar Biosciences Inc
4.86
-2.25 (-31.65%)
Last Update: 01 Jul 2025 23:26:00
Yesterday: 7.11
Day's Range: 4.36 - 5.3995
Send
sign up or login to leave a comment!
When Written:
1.43
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company that develops targeted cancer therapies. The company's proprietary phospholipid drug conjugate (PDC) platform technology enables the creation of cancer-targeting agents that can be selectively delivered to cancer cells. Cellectar's lead product candidate, CLR 131, is a PDC designed to deliver high-energy beta particles directly to cancer cells, resulting in selective tumor cell killing. The company is also developing other PDC-based product candidates for a range of cancer indications. Cellectar Biosciences Inc is headquartered in Madison, Wisconsin, and was founded in 2002.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








